- by John Reints
- Dec 29 2025
Post-Market Surveillance: How the FDA Monitors Generic Drugs After Approval
The FDA doesn't stop monitoring generic drugs after approval. It uses real-time data, adverse event reports, factory inspections, and AI to catch safety issues that clinical trials miss. Here's how it works.